Home
overview
With asthma being one of the most chronic diseases and affecting over 130 million people worldwide, drug developers and physicians have been prompted to review current treatments and improve therapeutic appoaches to asthma management.

SMi’s latest international pharmaceutical conference Asthma Therapeutics, will provide all the developments and latest advances of revolutionary therapeutic agents designed for the treatment of asthma.

Benefits of attending:

  • Keep up to date with industry developments in this important area
  • Explore the latest developments in asthma therapeutics
  • Learn about the latest delivery methods of asthma therapeutics
  • Meet the key players: Merck, AstraZeneca, Aventis, Roche, Pharmacia and Bayer

But that’s not all, with all the key players under one roof, you will be able to meet and discuss the issues with our top line up of speakers and delegates. Networking couldn’t be easier.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Ratko Djukanovic

Dr Ratko Djukanovic, Senior Lecturer in Medicine, Consultant Physician, University of Southampton

9:10 GENERAL OVERVIEW

Dr Joan Soriano

Dr Joan Soriano, Director, Worldwide Epidemiology, GlaxoSmithKline

  • Disease overview and burden
  • Causes of asthma
  • Existing therapies: drug groups, efficacy and safety
  • Future trends in disease and treatment
  • 9:40 UNMET NEEDS

    Dr Theodore Reiss

    Dr Theodore Reiss, Executive Director, Respiratory & Allergy, Merck

  • New methods for reduction of side effects caused by asthma therapeutics
  • Improving patient compliance
  • Generic versus branded medications
  • Recombinant monoclonal antibodies
  • Genes and asthma
  • Predictions for future direction of asthma research
  • 10:20 CLINICAL STUDIES

    Dr Trevor Hansel

    Dr Trevor Hansel, Medical Director, NHLI Clinical Studies Unit

  • Medical burden and needs, GCP and CPMP guidelines
  • Inhaled beta-agonists, inhaled steroids and leukotriene antagonists
  • Phase II proof of concept studies
  • Anti-IgE, anti-IL-5, CCR3 antagonism, IL-4 and TNFƒÑ directed therapy
  • Immunotherapy and disease modification
  • 11:00 Morning Coffee

    11:20 NOVEL TREATMENTS FOR ASTHMA

    Dr Alan Lewis

    Dr Alan Lewis, President, Signal Research Division of Celgene

  • New Products
  • Kinase inhibitors (JNK, p38, IKK)
  • Cytokine modulators
  • Options for oral immunotherapy
  • 12:00 A NEW DIMENSION IN LUNG IMAGING

    Dr Peter Hirst

    Dr Peter Hirst, Head, Inhalation Business Development, Pharmaceutical Profiles

  • A new dimension in lung imaging
  • Introducing radionuclide imaging studies
  • Improving 2D data analysis
  • Using 3D SPECT imaging
  • Development of a novel radiolabelling technique
  • 12:40 Networking Lunch

    13:40 THE ROLE OF IL-4R IN ASTHMA

    Dr Joel Tocker

    Dr Joel Tocker, Staff Scientist, Immunex

  • The immune response in asthma patients
  • Interactions between immune system proteins in asthma
  • IL-4R-mediated responses in asthma
  • Therapeutic efficiency of blocking IL-4 vs IL-4R
  • 14:20 TREATMENT FOR PERSISTENT ASTHMA

    Dr Daniel Levitt

    Dr Daniel Levitt, President, Research & Development, Protein Design Labs

  • Asthma is a T-cell mediated disease
  • TH2 cells are important components of the asthma pathophysiology
  • IL-4 is an important mediator of TH2 cell development and IgE production
  • Blocking IL-4 may suppress some of the more severe and chronic symptoms of asthma
  • Activated T cells are prominent in the lungs of asthmatics
  • Blocking IL-2- mediated stimulation of T cells may reduce T cell activation in this disease
  • 15:00 ANTIINFLAMMATORY THERAPIES

    Dr Paul Gater

    Dr Paul Gater, Principal Scientist, Roche

  • Chemokine receptors and their ligands
  • Chemokines as mediators of inflammation
  • Eotaxin, eosinophils and the CCR3 receptor
  • Development of small molecule CCR3 antagonists
  • Effect of CCR3 antagonists in animal models of asthma
  • Future directions
  • 15:40 Afternoon Tea

    16:00 THERAPEUTICS FOR CHRONIC LUNG DISEASES

    Dr Rikki Alexander

    Dr Rikki Alexander, Principal Scientist, Celltech

  • The role of PDE4 in modulating the activity of inflammatory and immunocompetent cells
  • Dual benefits of PDE4 selective inhibitors
  • Advantages of PDE4 inhibitors over existing therapies
  • Clinical efficacy of oral PDE4 inhibitors
  • Animal models
  • Reducing the side effects of PDE4 inhibitors
  • 16:40 SELICIDS

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer, Executive Vice President, Pharm. R & D, Celgene

  • Novel PDE4 inhibitors
  • Unique chemistry
  • PDE4 subtype selectivity
  • Cytokine modulation
  • Improved therapeutic index
  • Clinical progress
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Michael Placke

    Dr Michael Placke, Vice President & Chief Scientist, Battelle Pulmonary Therapeutics

    9:10 GENETIC TARGETS FOR ASTHMA THERAPY

    Dr Kevin Bacon

    Dr Kevin Bacon, Head, Asthma Research, Bayer

  • Identifying human genes associated with asthma
  • Genes showing potential as targets for asthma therapy
  • Target validation using viruses
  • Developing drugs from genes associated with asthma
  • Case study
  • Speeding up drug discovery via strategic alliances
  • 9:40 THE SEARCH FOR ANTI-ASTHMA DRUGS

    Dr Ivan Richards

    Dr Ivan Richards, Distinguished Scientist, Pharmacia

  • Potential therapeutic targets (chemical, cellular, molecular)
  • Approaches for the identification of novel targets
  • Target validation: the new challenge
  • Applicability of animal models in target identification
  • Influence of infections
  • Case studies; Future Directions
  • 10:20 ALLERGY VACCINATION

    Dr Torbjorn Bjerke

    Dr Torbjorn Bjerke, Executive Vice President, Research & Development, ALK Abello

  • Basic mode of action
  • Clinical efficacy; disease modification, curative potential
  • Novel approaches to allergy vaccination therapies
  • 11:00 Morning Coffee

    11:20 RESPIRATORY AND NASAL DRUG DELIVERY

    Dr Steve Nichols

    Dr Steve Nichols, New Technology Coordination Manager, Aventis

  • Alternatives to CFC inhalers
  • Extra fine droplets for improved delivery to the airways
  • Dose counters
  • Powder inhaler technologies
  • Bronchodilators, an example of delivery
  • Metered dose powder inhalers
  • 12:00 SUCCESSFUL PULMONARY DRUG DELIVERY

    Johnathan Rigby

    Johnathan Rigby, Head of Business Development (Europe & Japan), Profile Therapeutics

  • Understanding the problems facing delivery of drugs to the lungs
  • An overview of novel inhalation devices and technologies
  • Adaptive Aerosol Delivery (AAD™) - improving the interface between the patient the medication and the device
  • The patient centred benefits of 'Intelligent Inhalation' technology
  • 12:40 Networking Lunch

    13:40 DRY POWDER INHALER TECHNOLOGY

    Dr Mark Parry-Billings

    Dr Mark Parry-Billings, Director, Research & Development, Innovata Biomed

  • Dry powder inhalers in the context of other delivery formats
  • The future for dry powder inhalers
  • Critical development challenges and regulatory hurdles
  • New technologies which provide solutions
  • 14:20 CONTROLLING ASTHMA

    Dr David Fakes

    Dr David Fakes, Technical Affairs Director, IVAX Pharmaceuticals UK

  • How well is asthma currently controlled
  • BTS & NICE Guidance
  • The problems of drug delivery
  • Improving delivery and Easi-Breathe case study
  • Asthma drug delivery in the future
  • 15:00 INCREASING DRUG APPLICABILITY

    Dr Stephen Farr

    Dr Stephen Farr, Vice President, Research & Development, Aradigm

  • Liquid formulation technology
  • High drug loading per breath
  • Point-of-use aerosol generation and active breath control for efficiency and precision of drug delivery
  • Electronic compliance monitoring
  • Case studies involving drugs for respiratory disease
  • 15:40 Afternoon Tea

    16:00 RESPIRATORY PRODUCT DEVELOPMENT

    Dr Paul Wright

    Dr Paul Wright, Associate Director, Product Development, AstraZeneca

  • MDI propellants and the environment
  • Industrial property
  • CMC regulatory
  • Feedback from systemic and competitors
  • Complexity versus cost
  • 16:40 BUILDING AN ONLINE COMMUNITY

    Dr Neil Bacon

    Dr Neil Bacon, Chief Executive, Doctors.net.uk

  • How pharmaceutical companies use the web
  • A doctor-only community
  • Patient information: compliance tools/ educational literature
  • Integrating with offline methods and the sales force
  • 17:20 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Issues in Worldwide Licensing of Pharmaceutical Products
    Workshop

    Issues in Worldwide Licensing of Pharmaceutical Products

    The Hatton, at etc. venues
    22nd March 2002
    London, United Kingdom

    Transformation of the product marketing process ASTHMA (from scientist to marketeer)
    Workshop

    Transformation of the product marketing process ASTHMA (from scientist to marketeer)

    The Hatton, at etc. venues
    22nd March 2002
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.